{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:07:25Z","timestamp":1783685245704,"version":"3.55.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013281","name":"Joint Programming Initiative on Antimicrobial Resistance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.drudis.2025.104419","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:57:35Z","timestamp":1750967855000},"page":"104419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rediscovering nitroxoline: a metal-chelating agent bridging infection and cancer"],"prefix":"10.1016","volume":"30","author":[{"given":"Praveen","family":"Papareddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie R.M.","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlowe","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewgenij","family":"Proschak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Wichelhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8111-2842","authenticated-orcid":false,"given":"Heiko","family":"Herwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104419_b0005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104419_b0010","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050","volume":"404","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104419_b0015","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S0140-6736(24)01885-3","article-title":"Global burden of antimicrobial resistance and forecasts to 2050","volume":"404","author":"Kariuki","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104419_b0020","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(24)01705-7","article-title":"Antimicrobial resistance at a crossroads: the cost of inaction","volume":"404","author":"Craig","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104419_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100954","article-title":"Antimicrobial peptides for combating drug-resistant bacterial infections","volume":"68","author":"Xuan","year":"2023","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.drudis.2025.104419_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12091920","article-title":"An overview of the recent advances in antimicrobial resistance","volume":"12","author":"Oliveira","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/j.drudis.2025.104419_b0035","first-page":"182712","article-title":"Microbial profile and antimicrobial susceptibility pattern of multidrug-resistant organisms (MDROs) in bloodstream infections in paediatric and neonatal ICU of a tertiary care hospital, Uttarakhand","author":"Singh","year":"2024","journal-title":"J Pure Appl Microbio"},{"key":"10.1016\/j.drudis.2025.104419_b0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jgar.2013.10.005","article-title":"MDRO Beijing Consensus Meeting Report: global burden of multidrug-resistant organisms' current antimicrobial resistance problems in Asia-Pacific","volume":"2","author":"Gould","year":"2014","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.drudis.2025.104419_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309969","article-title":"Emergence of resistance to last-resort antimicrobials in bacteremia patients: a multicenter analysis of bloodstream pathogens in Korea","volume":"19","author":"Yoo","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104419_b0050","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1097\/MS9.0000000000000760","article-title":"Closing potential drivers of antimicrobial resistance: last-resort antimicrobials with the potential of being misused, the way forward \u2013 a short communication","volume":"85","author":"Miteu","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.drudis.2025.104419_b0055","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jgar.2024.05.008","article-title":"Genomic insights into in-ICU emergence of last-resort antimicrobial resistance in a rare, carbapenem resistant, ST16 Klebsiella pneumoniae strain from Jodhpur, India","volume":"38","author":"Chakrabortty","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.drudis.2025.104419_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2023.1153048","article-title":"Understanding the background and clinical significance of the WHO, WOAH, and EMA classifications of antimicrobials to mitigate antimicrobial resistance","volume":"10","author":"Gehring","year":"2023","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.drudis.2025.104419_b0065","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00139-23","article-title":"Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing","volume":"37","author":"Reza","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.drudis.2025.104419_b0070","article-title":"Comprehensive analysis of antimicrobial resistance in the Southwest Indian Ocean: focus on WHO critical and high priority pathogens","volume":"12","author":"Hoarau","year":"2024","journal-title":"Front Public Health"},{"key":"10.1016\/j.drudis.2025.104419_b0075","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/antibiotics13070659","article-title":"Antimicrobial resistance in the WHO African region: a systematic literature review 2016-2020","volume":"13","author":"Gahimbare","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.drudis.2025.104419_b0080","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.19.2200568","article-title":"Antimicrobial resistance of clinical Enterobacterales isolates from urine samples, Germany, 2016 to 2021","volume":"28","author":"Stoltidis-Claus","year":"2023","journal-title":"Euro Surveill"},{"key":"10.1016\/j.drudis.2025.104419_b0085","first-page":"445","article-title":"Nitroxoline: a potent antimicrobial agent against multidrug resistant Enterobacteriaceae","volume":"18","author":"Cherdtrakulkiat","year":"2019","journal-title":"EXCLI J"},{"key":"10.1016\/j.drudis.2025.104419_b0090","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/jac\/dky255","article-title":"Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline","volume":"73","author":"Wijma","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.drudis.2025.104419_b0095","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1186\/s12879-014-0628-7","article-title":"Review of the literature and individual patients' data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections","volume":"14","author":"Naber","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.drudis.2025.104419_b0100","first-page":"339","article-title":"Nitroxoline: treatment and prevention of urinary tract infections from the urologist's perspective","volume":"77","author":"Krajewski","year":"2024","journal-title":"Cent Eur J Urol"},{"key":"10.1016\/j.drudis.2025.104419_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113975","article-title":"Nitroxoline and its derivatives are potent inhibitors of metallo-beta-lactamases","volume":"228","author":"Proschak","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2025.104419_b0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijantimicag.2016.10.017","article-title":"Nitroxoline: a broad-spectrum biofilm-eradicating agent against pathogenic bacteria","volume":"49","author":"Abouelhassan","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.drudis.2025.104419_b0115","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1128\/AAC.01484-12","article-title":"The urinary antibiotic 5-nitro-8-hydroxyquinoline (Nitroxoline) reduces the formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc","volume":"56","author":"Sobke","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.drudis.2025.104419_b0120","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1021\/acsinfecdis.2c00206","article-title":"Transcript profiling of nitroxoline-treated biofilms shows rapid up-regulation of iron acquisition gene clusters","volume":"8","author":"Liu","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.drudis.2025.104419_b0125","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3390\/antibiotics11081105","article-title":"Chelation in antibacterial drugs: from nitroxoline to cefiderocol and beyond","volume":"11","author":"Antic","year":"2022","journal-title":"Antibiotics-Basel"},{"key":"10.1016\/j.drudis.2025.104419_b0130","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.cmi.2021.06.035","article-title":"Antifungal activity of nitroxoline against Candida auris isolates","volume":"27","author":"Fuchs","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.drudis.2025.104419_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpddr.2025.100578","article-title":"Nitroxoline evidence amoebicidal activity against Acanthamoeba castellanii through DNA damage and the stress response pathways","volume":"27","author":"Chen","year":"2025","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.drudis.2025.104419_b0140","article-title":"Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection","volume":"216","author":"Bonotto","year":"2023","journal-title":"Antivir Res"},{"key":"10.1016\/j.drudis.2025.104419_b0145","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28652","article-title":"Repurposing of the antibiotic nitroxoline for the treatment of mpox","volume":"95","author":"Bojkova","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.drudis.2025.104419_b0150","first-page":"476","article-title":"Clinical pharmacokinetics of nitroxoline","volume":"17","author":"Mrhar","year":"1979","journal-title":"Int J Clin Pharmacol Biopharm"},{"key":"10.1016\/j.drudis.2025.104419_b0155","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.3892\/ol.2016.4380","article-title":"Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing","volume":"11","author":"Zhang","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.drudis.2025.104419_b0160","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.7150\/ijbs.63125","article-title":"Discovery and validation of nitroxoline as a novel STAT3 inhibitor in drug-resistant urothelial bladder cancer","volume":"17","author":"Lin","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.drudis.2025.104419_b0165","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720932686","article-title":"BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis","volume":"11","author":"Li","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.drudis.2025.104419_b0170","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/jnci\/djq457","article-title":"Effect of nitroxoline on angiogenesis and growth of human bladder cancer","volume":"102","author":"Shim","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.drudis.2025.104419_b0175","article-title":"Camouflaged liposomes by 11A4-nanobody for co-delivery of cisplatin and nitroxoline in breast cancer tumors: an in vitro\/in vivo study","volume":"71","author":"Sayed-Tabatabaei","year":"2022","journal-title":"J Drug Deliv Sci Tec"},{"key":"10.1016\/j.drudis.2025.104419_b0180","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.7150\/jca.47025","article-title":"Nitroxoline inhibits bladder cancer progression by reversing EMT process and enhancing anti-tumor immunity","volume":"11","author":"Xu","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.drudis.2025.104419_b0185","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1002\/cmdc.202000402","article-title":"Synthesis of novel nitroxoline analogs with potent cathepsin B exopeptidase inhibitory activity","volume":"15","author":"Van de Walle","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2025.104419_b0190","doi-asserted-by":"crossref","first-page":"12334","DOI":"10.1021\/acs.inorgchem.9b01882","article-title":"Organoruthenated nitroxoline derivatives impair tumor cell invasion through inhibition of cathepsin B activity","volume":"58","author":"Mitrovic","year":"2019","journal-title":"Inorg Chem"},{"key":"10.1016\/j.drudis.2025.104419_b0195","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1039\/c2ob06978d","article-title":"Substituted oxines inhibit endothelial cell proliferation and angiogenesis","volume":"10","author":"Bhat","year":"2012","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.drudis.2025.104419_b0200","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1038\/s41598-020-59492-4","article-title":"Integrative proteomic and functional analyses provide novel insights into the action of the repurposed drug candidate nitroxoline in AsPC-1 cells","volume":"10","author":"Veschi","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104419_b0205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41389-018-0093-z","article-title":"Development and evaluation of a novel series of nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma","volume":"7","author":"Chen","year":"2018","journal-title":"Oncogenesis"},{"key":"10.1016\/j.drudis.2025.104419_b0210","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1038\/s41598-019-42088-y","article-title":"Assessment of early therapeutic response to nitroxoline in temozolomide-resistant glioblastoma by amide proton transfer imaging: a preliminary comparative study with diffusion-weighted imaging","volume":"9","author":"Kumari","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104419_b0215","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/14756366.2020.1780228","article-title":"Synthesis and evaluation of a large library of nitroxoline derivatives as pancreatic cancer antiproliferative agents","volume":"35","author":"Veschi","year":"2020","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.drudis.2025.104419_b0220","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/neuonc\/nou139","article-title":"Nitroxoline induces apoptosis and slows glioma growth in vivo","volume":"17","author":"Lazovic","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.drudis.2025.104419_b0225","doi-asserted-by":"crossref","first-page":"919","DOI":"10.7150\/ijbs.32259","article-title":"The novel combination of nitroxoline and PD-1 blockade, exerts a potent antitumor effect in a mouse model of prostate cancer","volume":"15","author":"Xu","year":"2019","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.drudis.2025.104419_b0230","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00203-022-03122-2","article-title":"Antimicrobial activity of clioquinol and nitroxoline: a scoping review","volume":"204","author":"Wykowski","year":"2022","journal-title":"Arch Microbiol"},{"key":"10.1016\/j.drudis.2025.104419_b0235","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1089\/mdr.2020.0037","article-title":"Zinc chelators as carbapenem adjuvants for metallo-\u03b2-lactamase-producing bacteria: in vitro and in vivo evaluation","volume":"26","author":"Principe","year":"2020","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.drudis.2025.104419_b0240","article-title":"Copper(II) enhances the antibacterial activity of nitroxoline against MRSA by promoting aerobic glycolysis","volume":"320\u2013321","author":"Huang","year":"2025","journal-title":"Biophys Chem"},{"key":"10.1016\/j.drudis.2025.104419_b0245","doi-asserted-by":"crossref","first-page":"39806","DOI":"10.18632\/oncotarget.5655","article-title":"Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK\/mTOR signaling pathway and the interplay with Chk2 activation","volume":"6","author":"Chang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104419_b0250","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3390\/antibiotics11081105","article-title":"Chelation in antibacterial drugs: from nitroxoline to cefiderocol and beyond","volume":"11","author":"Repac Antic","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.drudis.2025.104419_b0255","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1007\/s11030-023-10791-8","article-title":"Deciphering neuroprotective mechanism of nitroxoline in cerebral ischemia: network pharmacology and molecular modeling-based investigations","volume":"28","author":"Vadak","year":"2024","journal-title":"Mol Divers"},{"key":"10.1016\/j.drudis.2025.104419_b0260","doi-asserted-by":"crossref","first-page":"16613","DOI":"10.1038\/s41598-019-53147-9","article-title":"Decreased APE-1 by nitroxoline enhances therapeutic effect in a temozolomide-resistant glioblastoma: correlation with diffusion weighted imaging","volume":"9","author":"Cho","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104419_b0265","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/kjm2.12051","article-title":"Nitroxoline induces cell apoptosis by inducing MDM2 degradation in small-cell lung cancer","volume":"35","author":"Yu","year":"2019","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.drudis.2025.104419_b0270","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3390\/antiox12122081","article-title":"Induction of programmed cell death in Acanthamoeba culbertsoni by the repurposed compound nitroxoline","volume":"12","author":"Rodriguez-Exposito","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.drudis.2025.104419_b0275","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1038\/s41467-025-58730-5","article-title":"Uncovering nitroxoline activity spectrum, mode of action and resistance across Gram-negative bacteria","volume":"168","author":"Cacace","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104419_b0280","series-title":"Rationale for Clinical Breakpoints: Nitroxoline","author":"EUCAST","year":"2023"},{"key":"10.1016\/j.drudis.2025.104419_b0285","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02763-22","article-title":"Susceptibility of Aerococcus urinae and Aerococcus sanguinicola to standard antibiotics and to nitroxoline","volume":"11","author":"Ahmadzada","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.drudis.2025.104419_b0290","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03079-23","article-title":"Nitroxoline resistance is associated with significant fitness loss and diminishes in vivo virulence of Escherichia coli","volume":"12","author":"Deschner","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.drudis.2025.104419_b0295","first-page":"300","article-title":"Mutations that increase expression of the EmrAB-TolC efflux pump confer increased resistance to nitroxoline in Escherichia coli","volume":"75","author":"Puertolas-Balint","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.drudis.2025.104419_b0300","doi-asserted-by":"crossref","first-page":"7019","DOI":"10.1128\/AAC.03946-14","article-title":"In vitro activity of nitroxoline against Escherichia coli urine isolates from outpatient departments in Germany","volume":"58","author":"Kresken","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2025.104419_b0305","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s44337-024-00012-y","article-title":"Drug repurposing: a retrospective revolution in breast cancer medicine","volume":"1","author":"Shivani","year":"2024","journal-title":"Discover Med"},{"key":"10.1016\/j.drudis.2025.104419_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1352803","article-title":"Drug repurposing for rare: progress and opportunities for the rare disease community","volume":"11","author":"Jonker","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.drudis.2025.104419_b0315","unstructured":"Herriman R. Nitroxoline: Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program. https:\/\/outbreaknewstoday.substack.com\/p\/nitroxoline-free-living-amoeba-infections [Accessed 23 June 2025]."},{"key":"10.1016\/j.drudis.2025.104419_b0320","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40258-023-00816-6","article-title":"Drug repurposing of generic drugs: challenges and the potential role for government","volume":"21","author":"van der Pol","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.drudis.2025.104419_b0325","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2025.43.5_suppl.793","article-title":"Phase II study of oral APL-1202 plus tislelizumab or tislelizumab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC)","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104419_b0330","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2294854","article-title":"Novel nitroxoline derivative combating resistant bacterial infections through outer membrane disruption and competitive NDM-1 inhibition","volume":"13","author":"He","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.drudis.2025.104419_b0335","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jct.2017.05.037","article-title":"Solubility modelling, solution thermodynamics and preferential solvation for nitroxoline in solvent mixtures of ethyl acetate plus (methanol, ethanol, n-propanol and isopropanol)","volume":"113","author":"Li","year":"2017","journal-title":"J Chem Thermodyn"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T16:19:14Z","timestamp":1753978754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625001321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1359644625001321"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104419","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rediscovering nitroxoline: a metal-chelating agent bridging infection and cancer","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104419"}}